{"id":7169,"date":"2021-03-19T17:48:31","date_gmt":"2021-03-20T00:48:31","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=7169"},"modified":"2021-03-23T17:49:18","modified_gmt":"2021-03-24T00:49:18","slug":"safety-and-efficacy-of-favipiravir-in-moderate-to-severe-sars-cov-2-pneumonia","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/19\/safety-and-efficacy-of-favipiravir-in-moderate-to-severe-sars-cov-2-pneumonia\/","title":{"rendered":"Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">A multicenter randomized open-labeled clinical trial found that adding Favipiravir to the treatment protocol for in patients with moderate to severe SARS-CoV-2 infection did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir\/Ritonavir regimen. It also did not shorten time to clinical recovery or length of hospital stay.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Solaymani-Dodaran et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. International Immunopharmacology. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/j.intimp.2021.107522\"><i><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1016\/j.intimp.2021.107522<\/span><\/i><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A multicenter randomized open-labeled clinical trial found that adding Favipiravir to the treatment protocol for in patients with moderate to severe SARS-CoV-2 infection did not reduce the number of ICU admissions or intubations or In-hospital mortality compared to Lopinavir\/Ritonavir regimen. It also did not shorten time to clinical recovery or length of hospital stay. Solaymani-Dodaran&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/19\/safety-and-efficacy-of-favipiravir-in-moderate-to-severe-sars-cov-2-pneumonia\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[28],"topic":[19],"class_list":["post-7169","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-treatment","topic-testing-and-treatment"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=7169"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7169\/revisions"}],"predecessor-version":[{"id":7170,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/7169\/revisions\/7170"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=7169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=7169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=7169"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=7169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}